Aminoquinolinones useful as CD38 inhibitors
Aminoquinolinones are developed to inhibit CD38, addressing the need for treating metabolic and other disorders by increasing cellular NAD levels, effectively managing conditions like obesity and diabetes.
WO2026143049A1PCT designated stage Publication Date: 2026-07-02NEOLAIA INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/060994
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-15
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-02
Smart Images
Figure US2025060994_02072026_PF_FP_ABST
Abstract
The present invention relates to compounds that have activity as cluster of differentiation 38 (CD38) inhibitors, compositions of such compounds, and methods using such compounds for preventing or treating diseases and disorders such as, for example, diseases and disorders of metabolism.
Need to check novelty before this filing date? Find Prior Art